1	Serum	Serum	B-NP	NN	O	4	NMOD	0
2	and	and	I-NP	CC	O	4	NMOD	0
3	urine	urine	I-NP	NN	O	4	NMOD	0
4	levels	level	I-NP	NNS	O	0	ROOT	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	interleukin-8	interleukin-8	B-NP	NN	B-protein	5	PMOD	0
7	in	in	B-PP	IN	O	4	NMOD	0
8	patients	patient	B-NP	NNS	O	7	PMOD	0
9	with	with	B-PP	IN	O	8	NMOD	0
10	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	12	NMOD	0
11	's	's	B-NP	POS	O	12	NMOD	0
12	lymphoma	lymphoma	I-NP	NN	O	9	PMOD	0
13	.	.	O	.	O	4	P	0

1	Angiogenesis	Angiogenesis	B-NP	NN	O	2	SUB	3	Angiogenesis
2	plays	play	B-VP	VBZ	O	0	ROOT	0
3	an	an	B-NP	DT	O	5	NMOD	0
4	important	important	I-NP	JJ	O	5	NMOD	0
5	role	role	I-NP	NN	O	2	OBJ	0
6	in	in	B-PP	IN	O	2	VMOD	0
7	many	many	B-NP	JJ	O	8	NMOD	0
8	types	type	I-NP	NNS	O	6	PMOD	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	cancer	cancer	B-NP	NN	O	9	PMOD	0
11	.	.	O	.	O	2	P	0

1	Interleukin-8	Interleukin-8	B-NP	NN	B-protein	5	SUB	0
2	(	(	O	(	O	4	DEP	0
3	IL-8	IL-8	B-NP	NN	B-protein	4	DEP	0
4	)	)	O	)	O	1	NMOD	0
5	is	be	B-VP	VBZ	O	0	ROOT	0
6	known	know	I-VP	VBN	O	5	VC	0
7	to	to	I-VP	TO	O	8	VMOD	0
8	be	be	I-VP	VB	O	6	VMOD	0
9	a	a	B-NP	DT	O	13	NMOD	0
10	pro-inflammatory	pro-inflammatory	I-NP	JJ	B-protein	12	AMOD	0
11	and	and	I-NP	CC	I-protein	12	AMOD	0
12	pro-angiogenic	pro-angiogenic	I-NP	JJ	I-protein	13	NMOD	3	angiogenic
13	cytokine	cytokine	I-NP	NN	I-protein	17	SUB	0
14	,	,	O	,	O	17	P	0
15	and	and	O	CC	O	17	VMOD	0
16	IL-8	IL-8	B-NP	NN	B-protein	17	SUB	0
17	has	have	B-VP	VBZ	O	8	VMOD	0
18	been	be	I-VP	VBN	O	17	VC	0
19	reported	report	I-VP	VBN	O	18	VC	0
20	to	to	I-VP	TO	O	21	VMOD	0
21	be	be	I-VP	VB	O	19	VMOD	0
22	associated	associate	I-VP	VBN	O	21	VC	16	associated
23	with	with	B-PP	IN	O	22	VMOD	0
24	tumor	tumor	B-NP	NN	O	25	NMOD	0
25	progression	progression	I-NP	NN	O	29	NMOD	2	progression
26	,	,	O	,	O	29	P	0
27	prognosis	prognosis	B-NP	NN	O	29	NMOD	0
28	and	and	I-NP	CC	O	29	NMOD	0
29	survival	survival	I-NP	NN	O	23	PMOD	0
30	in	in	B-PP	IN	O	29	NMOD	0
31	several	several	B-NP	JJ	O	32	NMOD	0
32	types	type	I-NP	NNS	O	30	PMOD	0
33	of	of	B-PP	IN	O	32	NMOD	0
34	cancers	cancer	B-NP	NNS	O	33	PMOD	0
35	.	.	O	.	O	5	P	0

1	However	However	B-ADVP	RB	O	14	VMOD	0
2	,	,	O	,	O	14	P	0
3	the	the	B-NP	DT	O	4	NMOD	0
4	role	role	I-NP	NN	O	14	SUB	16	role
5	of	of	B-PP	IN	O	4	NMOD	0
6	IL-8	IL-8	B-NP	NN	B-protein	5	PMOD	0
7	in	in	B-PP	IN	O	4	NMOD	0
8	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	10	NMOD	0
9	's	's	B-NP	POS	O	10	NMOD	0
10	lymphoma	lymphoma	I-NP	NN	O	7	PMOD	0
11	(	(	O	(	O	13	DEP	0
12	NHL	NHL	B-NP	NN	O	13	DEP	0
13	)	)	O	)	O	10	NMOD	0
14	has	have	B-VP	VBZ	O	0	ROOT	0
15	not	not	I-VP	RB	O	14	VMOD	0
16	been	be	I-VP	VBN	O	14	VC	0
17	fully	fully	B-ADJP	RB	O	16	VMOD	0
18	determined	determine	I-ADJP	VBN	O	16	VC	0
19	.	.	O	.	O	14	P	0

1	Here	Here	B-ADVP	RB	O	4	VMOD	0
2	,	,	O	,	O	4	P	0
3	we	we	B-NP	PRP	O	4	SUB	0
4	evaluated	evaluate	B-VP	VBD	O	0	ROOT	0
5	the	the	B-NP	DT	O	6	NMOD	0
6	usefulness	usefulness	I-NP	NN	O	4	OBJ	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	measuring	measure	B-VP	VBG	O	7	PMOD	0
9	serum	serum	B-NP	NN	O	13	NMOD	0
10	and	and	I-NP	CC	O	13	NMOD	0
11	urine	urine	I-NP	NN	O	13	NMOD	0
12	IL-8	IL-8	I-NP	NN	B-protein	13	NMOD	0
13	levels	level	I-NP	NNS	O	8	OBJ	0
14	in	in	B-PP	IN	O	8	VMOD	0
15	patients	patient	B-NP	NNS	O	14	PMOD	0
16	with	with	B-PP	IN	O	15	NMOD	0
17	NHL	NHL	B-NP	NN	O	16	PMOD	0
18	.	.	O	.	O	4	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	developed	develop	B-VP	VBD	O	0	ROOT	0
3	reference	reference	B-NP	NN	O	4	NMOD	0
4	intervals	interval	I-NP	NNS	O	2	OBJ	0
5	for	for	B-PP	IN	O	4	NMOD	0
6	serum	serum	B-NP	NN	O	10	NMOD	0
7	and	and	I-NP	CC	O	10	NMOD	0
8	urine	urine	I-NP	NN	O	10	NMOD	0
9	IL-8	IL-8	I-NP	NN	B-protein	10	NMOD	0
10	level	level	I-NP	NN	O	5	PMOD	0
11	in	in	B-PP	IN	O	4	NMOD	0
12	131	131	B-NP	CD	O	14	NMOD	0
13	control	control	I-NP	NN	O	14	NMOD	0
14	individuals	individual	I-NP	NNS	O	11	PMOD	0
15	.	.	O	.	O	2	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	measured	measure	B-VP	VBD	O	16	VMOD	0
3	serum	serum	B-NP	NN	O	4	NMOD	0
4	IL-8	IL-8	I-NP	NN	B-protein	8	NMOD	0
5	and	and	O	CC	O	7	NMOD	0
6	urine	urine	B-NP	NN	O	7	NMOD	0
7	IL-8	IL-8	I-NP	NN	B-protein	8	NMOD	0
8	levels	level	I-NP	NNS	O	2	OBJ	0
9	in	in	B-PP	IN	O	2	VMOD	0
10	patients	patient	B-NP	NNS	O	9	PMOD	0
11	with	with	B-PP	IN	O	10	NMOD	0
12	NHL	NHL	B-NP	NN	O	11	PMOD	0
13	,	,	O	,	O	16	P	0
14	and	and	O	CC	O	16	VMOD	0
15	we	we	B-NP	PRP	O	16	SUB	0
16	compared	compare	B-VP	VBD	O	0	ROOT	0
17	the	the	B-NP	DT	O	18	NMOD	0
18	concentrations	concentration	I-NP	NNS	O	16	OBJ	0
19	with	with	B-PP	IN	O	18	NMOD	0
20	those	those	B-NP	DT	O	19	PMOD	0
21	of	of	B-PP	IN	O	20	NMOD	0
22	control	control	B-NP	NN	O	23	NMOD	0
23	individuals	individual	I-NP	NNS	O	21	PMOD	0
24	.	.	O	.	O	16	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	reference	reference	I-NP	NN	O	3	NMOD	0
3	intervals	interval	I-NP	NNS	O	16	SUB	0
4	for	for	B-PP	IN	O	3	NMOD	0
5	serum	serum	B-NP	NN	O	6	NMOD	0
6	IL-8	IL-8	I-NP	NN	B-protein	9	NMOD	0
7	and	and	O	CC	O	9	NMOD	0
8	urine	urine	B-NP	NN	O	9	NMOD	0
9	IL-8	IL-8	I-NP	NN	B-protein	4	PMOD	0
10	corrected	correct	B-VP	VBN	O	9	NMOD	0
11	by	by	B-PP	IN	O	10	VMOD	0
12	creatinine	creatinine	B-NP	NN	O	11	PMOD	0
13	(	(	O	(	O	15	DEP	0
14	Cr	Cr	B-NP	NN	O	15	DEP	0
15	)	)	O	)	O	12	NMOD	0
16	were	be	B-VP	VBD	O	0	ROOT	0
17	15.9-430.3	15.9-430.3	B-NP	CD	O	18	NMOD	0
18	pg/mL	pg/mL	I-NP	NN	O	22	NMOD	0
19	and	and	O	CC	O	22	NMOD	0
20	0.0-28.4	0.0-28.4	B-NP	CD	O	22	NMOD	0
21	pg/mg	pg/mg	I-NP	NN	O	22	NMOD	0
22	Cr	Cr	I-NP	NN	O	16	PRD	0
23	,	,	O	,	O	22	P	0
24	respectively	respectively	B-ADVP	RB	O	22	NMOD	0
25	.	.	O	.	O	16	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	concentrations	concentration	I-NP	NNS	O	6	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	urine	urine	B-NP	NN	O	5	NMOD	0
5	IL-8/Cr	IL-8/Cr	I-NP	NN	O	3	PMOD	0
6	were	be	B-VP	VBD	O	0	ROOT	0
7	significantly	significantly	B-ADJP	RB	O	8	AMOD	0
8	higher	high	I-ADJP	JJR	O	6	PRD	0
9	in	in	B-PP	IN	O	8	AMOD	0
10	patients	patient	B-NP	NNS	O	9	PMOD	0
11	than	than	B-PP	IN	O	8	AMOD	0
12	in	in	B-PP	IN	O	11	PMOD	0
13	controls	control	B-NP	NNS	O	12	PMOD	0
14	(	(	O	(	O	25	DEP	0
15	48.9+/-194.4	48.9+/-194.4	B-NP	CD	O	19	NMOD	0
16	vs.	vs.	I-NP	IN	O	19	NMOD	0
17	5.2+/-13.8	5.2+/-13.8	I-NP	CD	O	19	NMOD	0
18	pg/mg	pg/mg	I-NP	NN	O	19	NMOD	0
19	Cr	Cr	I-NP	NN	O	21	NMOD	0
20	,	,	O	,	O	21	P	0
21	P	P	B-NP	NN	O	25	DEP	0
22	less	less	B-ADJP	JJR	O	21	NMOD	0
23	than	than	B-PP	IN	O	22	AMOD	0
24	0.001	0.001	B-NP	CD	O	23	PMOD	0
25	)	)	O	)	O	13	NMOD	0
26	.	.	O	.	O	6	P	0

1	However	However	B-ADVP	RB	O	4	VMOD	0
2	,	,	O	,	O	4	P	0
3	there	there	B-NP	EX	O	4	SUB	0
4	were	be	B-VP	VBD	O	0	ROOT	0
5	no	no	B-NP	DT	O	7	NMOD	0
6	significant	significant	I-NP	JJ	O	7	NMOD	0
7	differences	difference	I-NP	NNS	O	4	PRD	0
8	in	in	B-PP	IN	O	4	VMOD	0
9	serum	serum	B-NP	NN	O	11	NMOD	0
10	IL-8	IL-8	I-NP	NN	O	11	NMOD	0
11	concentrations	concentration	I-NP	NNS	O	8	PMOD	0
12	between	between	B-PP	IN	O	11	NMOD	0
13	NHL	NHL	B-NP	NN	O	14	NMOD	0
14	patients	patient	I-NP	NNS	O	16	NMOD	0
15	and	and	O	CC	O	16	NMOD	0
16	controls	control	B-NP	NNS	O	12	PMOD	0
17	(	(	O	(	O	24	DEP	0
18	159.2+/-40.4	159.2+/-40.4	B-NP	CD	O	21	NMOD	0
19	vs.	vs.	I-NP	IN	O	21	NMOD	0
20	99.6+/-107.1	99.6+/-107.1	B-NP	CD	O	21	NMOD	0
21	pg/mL	pg/mL	I-NP	NN	O	23	NMOD	0
22	;	;	O	:	O	23	P	0
23	P=0.099	P=0.099	B-NP	NN	O	24	DEP	0
24	)	)	O	)	O	16	NMOD	0
25	.	.	O	.	O	4	P	0

1	Receiver	Receiver	B-NP	NN	O	8	SUB	0
2	operating	operate	B-VP	VBG	O	1	NMOD	0
3	characteristic	characteristic	B-ADJP	JJ	O	7	NMOD	0
4	(	(	O	(	O	6	DEP	0
5	ROC	ROC	B-NP	NN	O	6	DEP	0
6	)	)	O	)	O	3	NMOD	0
7	analysis	analysis	B-NP	NN	O	2	OBJ	0
8	gave	give	B-VP	VBD	O	0	ROOT	0
9	0.83	0.83	B-NP	CD	O	11	AMOD	0
10	and	and	I-NP	CC	O	11	AMOD	0
11	0.43	0.43	I-NP	CD	O	14	NMOD	0
12	ROC	ROC	I-NP	NN	O	14	NMOD	0
13	area	area	I-NP	NN	O	14	NMOD	0
14	values	value	I-NP	NNS	O	8	OBJ	0
15	for	for	B-PP	IN	O	8	VMOD	0
16	urine	urine	B-NP	NN	O	17	NMOD	0
17	IL-8/Cr	IL-8/Cr	I-NP	NN	O	20	NMOD	0
18	and	and	O	CC	O	20	NMOD	0
19	serum	serum	B-NP	NN	O	20	NMOD	0
20	IL-8	IL-8	I-NP	NN	B-protein	15	PMOD	0
21	,	,	O	,	O	8	P	0
22	respectively	respectively	B-ADVP	RB	O	8	VMOD	0
23	.	.	O	.	O	8	P	0

1	There	There	B-NP	EX	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	no	no	B-NP	DT	O	4	NMOD	0
4	correlation	correlation	I-NP	NN	O	2	PRD	0
5	between	between	B-PP	IN	O	4	NMOD	0
6	the	the	B-NP	DT	O	10	NMOD	0
7	serum	serum	I-NP	NN	O	10	NMOD	0
8	and	and	I-NP	CC	O	10	NMOD	0
9	urine	urine	I-NP	NN	O	10	NMOD	0
10	concentrations	concentration	I-NP	NNS	O	5	PMOD	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	IL-8	IL-8	B-NP	NN	B-protein	15	NMOD	0
13	and	and	O	CC	O	15	NMOD	0
14	clinical	clinical	B-NP	JJ	O	15	NMOD	0
15	variables	variable	I-NP	NNS	O	11	PMOD	0
16	,	,	O	,	O	2	P	0
17	the	the	B-NP	DT	O	19	NMOD	0
18	only	only	I-NP	JJ	O	19	NMOD	0
19	exception	exception	I-NP	NN	O	20	SUB	0
20	being	be	B-VP	VBG	O	2	VMOD	0
21	the	the	B-NP	DT	O	24	NMOD	0
22	international	international	I-NP	JJ	O	24	NMOD	0
23	prognostic	prognostic	I-NP	JJ	O	24	NMOD	0
24	index	index	I-NP	NN	O	20	PRD	0
25	(	(	O	(	O	27	DEP	0
26	IPI	IPI	B-NP	NN	B-protein	27	DEP	0
27	)	)	O	)	O	24	NMOD	0
28	,	,	O	,	O	24	P	0
29	which	which	B-NP	WDT	O	24	NMOD	0
30	showed	show	B-VP	VBD	O	29	SBAR	0
31	a	a	B-NP	DT	O	33	NMOD	0
32	marginal	marginal	I-NP	JJ	O	33	NMOD	0
33	correlation	correlation	I-NP	NN	O	30	OBJ	0
34	with	with	B-PP	IN	O	33	NMOD	0
35	urine	urine	B-NP	NN	O	37	NMOD	0
36	IL-8/Cr	IL-8/Cr	I-NP	NN	O	37	NMOD	0
37	levels	level	I-NP	NNS	O	34	PMOD	0
38	(	(	O	(	O	40	DEP	0
39	P=0.07	P=0.07	B-NP	NN	O	40	DEP	0
40	)	)	O	)	O	37	NMOD	0
41	.	.	O	.	O	2	P	0

1	This	This	B-NP	DT	O	2	NMOD	0
2	study	study	I-NP	NN	O	3	SUB	0
3	indicated	indicate	B-VP	VBD	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	VMOD	0
5	urine	urine	B-NP	NN	O	7	NMOD	0
6	IL-8/Cr	IL-8/Cr	I-NP	NN	O	7	NMOD	0
7	levels	level	I-NP	NNS	O	8	SUB	0
8	might	might	B-VP	MD	O	4	SBAR	0
9	be	be	I-VP	VB	O	8	VC	0
10	useful	useful	B-ADJP	JJ	O	9	PRD	0
11	as	as	B-PP	IN	O	10	AMOD	0
12	a	a	B-NP	DT	O	14	NMOD	0
13	diagnostic	diagnostic	I-NP	JJ	O	14	NMOD	0
14	marker	marker	I-NP	NN	O	11	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	0
16	NHL	NHL	B-NP	NN	O	15	PMOD	0
17	.	.	O	.	O	3	P	0

